Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 795 |
| INN | Brenetafusp |
| Status | Clinical |
| Drug code(s) | IMC-F106C |
| Brand name | None |
| mAb sequence source | mAb - source TBD |
| General Molecular Category | Bispecific, Immunoconjugate |
| Format, general category | Fragment fusion |
| Format details | scFv-TCR |
| Isotype (Fc) | None |
| Light chain isotype | TBD |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | T cell receptor |
| Discovery method/technology | None |
| Target(s) | PRAME, CD3 |
| Indications of clinical studies | PRAME-Positive Cancers |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | February 25, 2020 |
| Start of Phase 2 | |
| Start of Phase 3 | December 18, 2023 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Immunocore Ltd |
| Licensee/Partner | None |
| Comments about company or candidate | NCT06112314 Phase 3 study in melanoma started in Dec 2023. NCT04262466 Phase 1/2 study started Feb 25 2020 recruiting as of last update in Dec 2022. |
| Full address of company | 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK Europe United Kingdom https://www.immunocore.com/contact-us |
IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME PRAME = PReferentially expressed Antigen in Melanoma. Developed using ImmTac technology; molecule combines a T cell receptor-targeting system with an anti-CD3 antibody-based binding site.
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |